Back

Deep tissue sequencing improves genetic diagnostic yield in focal cortical dysplasia

Galea, B. G.; Reid, J.; Gooley, S.; Witkowski, T.; Lane, T.; Macdonald, S.; Green, T. E.; Ye, Z.; Adikari, T.; Bulluss, K.; Mullen, S. A.; Bennett, C. A.; Forster, B.; Bradshaw, G.; Lin, W.; De Silva, W.; Ramirez, R. B.; Khoshkhoo, S.; Gupta, S.; Krivanek, M.; Menezes, M.; Kothur, K.; Gill, D.; Pope, K.; Gillies, G.; Coleman, M.; Lee, W.-S.; Stephenson, S. M.; Maixner, W.; Harvey, A. S.; Macdonald-Laurs, E.; Howell, K. B.; D'Arcy, C.; Lockhart, P. J.; Leventer, R. J.; Kalnins, R. M.; Clark, J.; Bennett, M. F.; Bahlo, M.; Scheffer, I. E.; Perucca, P.; Berkovic, S. F.; Hildebrand, M. S.

2025-11-22 genetic and genomic medicine
10.1101/2025.11.17.25340194 medRxiv
Show abstract

Focal cortical dysplasias (FCDs) are malformations of cortical development associated with drug-resistant focal epilepsy. We analysed surgical tissue from 28 consecutive cases recruited from adult and pediatric epilepsy surgery programs. We performed high-depth sequencing of lesional tissue, validated somatic variants using droplet digital PCR, and investigated genotype-phenotype correlations. A pathogenic or likely pathogenic variant was detected in 71% (n=20/28) of cases. Of these, six cases with FCDIIa or FCDIIb had germline variants in NPRL3 (n=4) or DEPDC5 (n=2). Somatic variants were identified in 50% (n=14/28) of cases. The genetic yield for FCDIIb was 85% of cases having a pathogenic mTOR pathway variant detected (n=12/14), and for FCDIIa 66% (n=6/9). This was achieved through high depth sequencing approaches that allowed detection of somatic variants with very low (down to 0.4%) variant allele fractions (VAFs). No pathogenic variants were detected in 3 cases with FCDI. 70% (n=18/26) of the cases with [≥]12 months follow up experienced a favourable seizure outcome (Engel 1-2) following surgery. Of note, n=10 patients required repeat surgery to resect residual dysplasia. Determining a genetic diagnosis reveals aetiology and paves the way to precision therapies that may benefit those with FCD who do not respond to current treaments.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.